Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

humanity-based sales activities the “LIVES System*” and it is a top
priority. This policy aims to ensure an increased level of patient
satisfaction by quickly delivering effective medicines that are expected
to maximize the benefits to patients. We intend to create a
unique pharmaceutical sales method based on improved customer
satisfaction and insure reliability by appraising our MR activity
through measuring their contributions to patients’ QOL.
4. Stressing Relationships with Stakeholders
Eisai recognizes that interactive communication with its stakeholders,
including patients, shareholders, health care providers and employees,
is important, and intends to reinforce relationship-based management
in which their needs are carefully considered. Moreover, we
will continue to actively contribute to local communities and support
environmental preservation as a trusted corporate citizen.
5. Strengthening Corporate Governance
Greater transparency and accountability are envisioned for business
activities in the 21st century. Accordingly, we understand that establishing
effective corporate governance systems is critical. Eisai has
appointed two Non-Executive Directors and increased the number of
outside auditors to three of the five. In addition, we have clearly
distinguished the roles of the Board of Directors and the Corporate
Officers, reinforced the roles of the Non-Executive Directors on the
Board of Directors and implemented measures to strengthen the
Corporate Governance Committee. The Corporate Governance Committee,
which is chaired by Ichiro Kataoka, a Non-Executive Director,
consists of four members, and its major purpose is to ensure transparent
decision-making in the appointment of officers and their
remuneration. A stock option system was introduced in fiscal 2000
with regard to the remuneration of officers; this system and bonus
amounts are now determined following examination by the Committee.
We will continue to make efforts to enhance transparency and
accountability to our stakeholders.
Eisai Annual Report 2001
*
LIVES System: Eisai defines this system
as the “dignity and quality of life for
patients for whom various benefits are
expected to be achieved through
product usage”
7